Cancer Treatments

Cancer, in its many forms, is one of the great remaining areas of unmet medical need. Shortfalls in the safety and efficacy of treatment protocols based on chemotherapy and radiation therapy call for new, improved approaches.

Cancer immunotherapy using vaccine technologies such as the alphavaccine platform system is an exciting alternative to current treatments that is poised to redefine the marketplace.

We are currently collaborating with several academic institutions and investigators to explore such cancer treatments. For instance, we are co-investigators with the Duke University Comprehensive Cancer Center on two clinical vaccine development grants from the National Cancer Institute and the Department of Defense, Breast Cancer Research Program, to evaluate our system for colon cancer and breast cancer vaccines. The colon cancer phase 1/2 clinical trial initiated enrollment of patients in August of 2007.

In addition, we have academic collaborations with research groups at Memorial Sloan Kettering Cancer Center, University of California, Irvine, and the University of Southern California.